drugset / Trial / NCT01289223
A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the efficacy of bendamustine against treatment of physician's choice on progression-free survival in subjects with indolent B-cell NHL.
Timeline
- Start
- 2011-02
- Primary completion
- 2018-07-31
- Completion
- 2018-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 120 mg/m2 | Intravenous |